ArticleBMC public health2025
Global burden of Alzheimer's disease and other dementias in adults aged 65 years and over, and health inequality related to SDI, 1990-2021: analysis of data from GBD 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Depression as a prognostic factor for conversion from mild cognitive impairment to all-cause dementia and Alzheimer's disease: a systematic review and meta-analysis of longitudinal studies.Frontiers in public health · 2026Pooled it
- Temporal trends in the prevalence of Alzheimer's disease, 1980-2024: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Long-term trends in selected neurological disorders in Italy (1990-2023): analysis of the global burden of disease (GBD) 2023 data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Trends in Population-Level Mortality Rates for Deaths With Both Alzheimer's Disease and Cancer Recorded on Death Certificates Among U.S. Adults Aged ≥ 65 Years, 1999-2023.Nursing open · 2026Article
- Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review.Journal of clinical medicine · 2026Review
- When copper turns killer: Decoding copper dyshomeostasis and cuproptosis in neurodegenerative pathogenesis and precision metal interventions.Neural regeneration research · 2026Article
- Oxidative Stress in Alzheimer's Disease: Can Dietary Interventions Provide Neuroprotection?Nutrients · 2026Review
- Protein Consumption and Cognitive Health in Aging: Associations with Sarcopenia and Dietary Options, a Narrative Review.Nutrients · 2026Review
- Global Burden of Pulmonary Arterial Hypertension in Older Adults and Its Causal Association With Body Mass Index.Pulmonary circulation · 2026Article
- Salivary Cortisol and Cognitive Decline and Alzheimer Disease in Older Adults.JAMA network open · 2026Article
- The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer's Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Expression patterns of risk genes associated with three evolutionarily relevant syndromes in rhesus macaque and human brains.Translational psychiatry · 2026Article
- Risk of a Dementia Diagnosis in Community-Dwelling Older Adults With Normal MMSE Scores in the United States.American journal of medicine open · 2026Article
- Design, synthesis, and multitarget evaluation of thiosemicarbazone-sulfonamide hybrids as potent cholinesterase and MAO-A inhibitors with neuroblastoma-associated cytotoxicity.Scientific reports · 2026Article
- Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.Alzheimer's research & therapy · 2026Article
- Protective effects of curcumin and resveratrol on neurodegeneration and cognitive dysfunction in a streptozotocin-induced alzheimer rat model.Scientific reports · 2026Article
- Explainable machine learning identifies candidate shared neuroanatomical features in Alzheimer's and Parkinson's via importance inversion transfer.bioRxiv : the preprint server for biology · 2026Article
- Investigating the Impact of ABCB1 3435C>T (rs1045642) Variant on Severity and Cognitive Decline in Egyptian Alzheimer's Disease Patients.Molecular neurobiology · 2026Article
- Redefining Idiopathic Normal Pressure Hydrocephalus Using AI-Driven Brain Volumetry.Biomedicines · 2026Article
- Exercise Interventions for Cognitive and Functional Outcomes in Dementia: A Systematic Review and Meta-Analysis Exploring Dose Metrics, Heterogeneity, and Implementation-Relevant Factors.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe disease burden of dementia in the elderly is predicted to rise, and dementia among older adults has become a crucial issue for public health. Quantifying the disease burden of dementia in the elderly can provide relevant areas and countries with scientific data to help them adjust their healthcare strategies.
methodsWe analyzed the disease burden of Alzheimer's disease and other dementias among individuals aged 65 and older from 1990 to 2021; the relationship between mortality rates and disability-adjusted life years (DALYs) with socio-demographic index (SDI); conducted a frontier analysis of the disease burden across 204 countries; and quantified inequalities in age-standardized DALYs for Alzheimer's disease and other dementias using the slope inequality index and concentration index.
resultsGlobally, age-standardized DALYs and mortality rates for individuals aged 65 and older have declined over time. We find that the disease burden of dementia is significantly associated with SDI. High SDI countries have 169% higher baseline levels of dementia burden compared to low SDI countries, as estimated based on their current level of social development. Finally, our health inequality analyses reveal that while the overall trend of DALYs for dementia increases with SDI, the burden is primarily concentrated in populations with lower SDI, as non-developed countries account for the majority of the population.
conclusionThe global population aged 65 and older experiences a significant reduction in healthy life expectancy due to dementia. The burden of disease in most countries is higher than the minimum disease burden associated with SDI in those countries. The burden of disease in low and middle SDI countries has been showing an increasing trend. The gap in disease burden among regions with different SDI levels is also continuously narrowing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.